glp-1 obesity drug news october 21 2025 Reality Check: Doctors Challenge "Magic Drug" Narrative Weight loss with GLP-1 medicines

Abstract Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their associated complications

VE303 is an oral, defined consortium of eight clonal bacterial strains intended to modulate the gutliverbrain axis by promoting strain engraftment and beneficial metabolites such as butyrate [152]

Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study

a smaller deep subcutaneous (under skin) 29 gauge inch needle

This makes the peptide useful in receptor activation assays, cAMP studies, and pathway analyses focused on incretin-glucagon signaling integration [3][5][6]

Consequently, it attracts growing interest in cardiometabolic and cardiovascular disease research